HER2 Homodimer and HER2 Total Protein Assays
 

SOUTH SAN FRANCISCO, Dec. 14 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. today presented the results of a study detailing the HERmark(TM) Assay's ability to identify metastatic breast cancer patients who are most likely to respond to Herceptin(R). The study results were presented this week at the San Antonio Breast Cancer Symposium. Also this week, Monogram received confirmation from the College of Pathologists (CAP) that the HERmark assays are approved for routine patient testing in Monogram's CLIA certified clinical reference laboratory.

Read entire article:

http://money.cnn.com/news/newsfeeds/...14122007-1.htm